In this paper, we present an exploratory study on the potential impact of holographic heart models and mixed reality technology on medical training, and in particular in teaching complex Congenital Heart Diseases (CHD) to medical students. Fifty-nine medical students were randomly allocated into three groups. Each participant in each group received a 30-minute lecture on a CHD condition interpretation and transcatheter treatment with different instructional tools. The participants of the first group attended a lecture in which traditional slides were projected onto a flat screen (group “regular slideware”, RS). The second group was shown slides incorporating videos of holographic anatomical models (group “holographic videos”, HV). Finally, those in the third group wore immersive, head-mounted devices (HMD) to interact directly with holographic anatomical models (group “mixed reality”, MR). At the end of the lecture, the members of each group were asked to fill in a multiple-choice questionnaire aimed at evaluating their topic proficiency, as a proxy to evaluate the effectiveness of the training session (in terms of acquired notions); participants from group MR were also asked to fill in a questionnaire regarding the recommendability and usability of the MS Hololens HMDs, as a proxy of satisfaction regarding its use experience (UX). The findings show promising results for usability and user acceptance.

Although survival has significantly improved in the last four decades, the diagnosis of Ebstein’s anomaly is still associated with a 20-fold increased risk of mortality, which generally drops after neonatal period and increases subtly thereafter. With increasing age of presentation, appropriate timing of intervention is challenged by a wide spectrum of disease and paucity of data on patient-tailored interventional strategies. The present review sought to shed light on the wide grey zone of post-neonatal Ebstein’s manifestations, highlighting current gaps and achievements in knowledge for adequate risk assessment and appropriate therapeutic strategy. A ‘wait-and-see’ approach has been adopted in many circumstances, though its efficacy is now questioned by the awareness that Ebstein’s anomaly is not a benign disease, even when asymptomatic. Moreover, older age at intervention showed a negative impact on post-surgical outcome. In order to tackle the extreme heterogeneity of Ebstein’s anomaly, this review displays the multimodality imaging assessment necessary for a proper anatomical classification and the multidisciplinary approach needed for a comprehensive risk stratification and monitoring strategy. Currently available predictors of clinical outcome are summarised for both operated and unoperated patients, with the aim of supporting the decisional process on the choice of appropriate therapy and optimal timing for intervention.

The population of patients with a systemic right ventricle (sRV) in biventricular circulation includes those who have undergone an atrial switch operation for destro-transposition of the great arteries (d-TGA) and those with congenitally corrected transposition of the great arteries (ccTGA). Despite the life expectancy of these patients is significantly increased, the long-term prognosis remains suboptimal due to late complications such as heart failure, arrhythmias, and premature death. These patients, therefore, need a close follow-up to early identify predictive factors of adverse outcomes and to implement all preventive therapeutic strategies. This review analyzes the late complications of adult patients with an sRV and TGA and clarifies which are risk factors for adverse prognosis and which are the therapeutic strategies that improve the long-term outcomes. For prognostic purposes, it is necessary to monitor sRV size and function, the tricuspid valve regurgitation, the functional class, the occurrence of syncope, the QRS duration, N-terminal pro B-type natriuretic peptide levels, and the development of arrhythmias. Furthermore, pregnancy should be discouraged in women with risk factors. Tricuspid valve replacement/repair, biventricular pacing, and implantable cardioverter defibrillator are the most important therapeutic strategies that have been shown, when used correctly, to improve long-term outcomes.

The Venus P-Valve is a novel self-expanding prosthesis designed for transcatheter pulmonary valve implantation (TPVI) in patients with severe pulmonary regurgitation and dilated right ventricular outflow tracts. This case series assessed the incidence of subclinical leaflet thrombosis, defined as hypoattenuated leaflet thickening (HALT), and reduced leaflet motion 6 months after TPVI in 7 patients treated between January and April 2023. HALT was detected via computed tomography angiography in 71% of patients, primarily affecting the right cusp. Despite the high incidence of HALT, no significant valve dysfunctions or adverse clinical events were documented. Patients with HALT were treated with oral anticoagulation, resulting in a reduction of HALT at follow-up. These findings underscore the uncertainty regarding the short-term clinical relevance of HALT and reduced leaflet motion, emphasizing the need for individualized antithrombotic strategies. Larger studies are required to evaluate the long-term impact and optimal therapeutic approach for patients undergoing TPVI with the Venus P-Valve.